AnaptysBio (NASDAQ:ANAB) Posts Quarterly Earnings Results, Beats Estimates By $5.57 EPS

AnaptysBio (NASDAQ:ANAB) released its quarterly earnings results on Monday. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $5.57, FiscalAI reports. The firm had revenue of $27.49 million during the quarter, compared to analyst estimates of $14.06 million.

AnaptysBio Stock Performance

NASDAQ:ANAB traded down $0.28 during mid-day trading on Monday, hitting $54.92. 493,264 shares of the stock were exchanged, compared to its average volume of 694,752. The firm’s 50-day simple moving average is $56.14 and its 200 day simple moving average is $59.25. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -50.85 and a beta of 0.71. AnaptysBio has a fifty-two week low of $13.66 and a fifty-two week high of $72.36.

Analyst Ratings Changes

Several equities research analysts have commented on ANAB shares. Wolfe Research reissued an “outperform” rating and set a $78.00 price target on shares of AnaptysBio in a research report on Monday, August 31st. Zacks Research cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. HC Wainwright reaffirmed a “buy” rating and set a $95.00 price target on shares of AnaptysBio in a research report on Monday, August 24th. TD Cowen cut their price target on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.85.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.